IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
phase I trial of AT 7519 in pa tients with re frac tory solid tu mors with ad e quate bone mar row, hepatic and
renal function, were reported.
HSP 990, a heat shock pro tein 90 in hib i tor, was in pre clin i cal stud ies in 2008 for the treat ment of can cer.
Clin i cal tri als are ex pected to be gin in 2009.
AVP 28225 is a lead can di date re sult ing from a col lab o ra tion of Novartis and Avanir (USA) on the de vel -
op ment of orally ac tive small mol e cules that in hibit macrophage mi gra tion in hib i tory fac tor (MIF), as po -
ten tial ther a pies for in flam ma tory dis eases such as ar thri tis. Pre clin i cal stud ies of a se ries of agents are
on go ing in Swit zer land. AVANIR part nered this pro gram with Novartis in 2005; in March 2007, Novartis
as sumed all con tin u ing re search and development activities for the program.
Li cens ing: Avanir signed a re search, de vel op ment and com mer cial iza tion agree ment with Novartis in
2005 to de velop orally ac tive small mol e cules that in hibit macrophage mi gra tion in hib i tory fac tor (MIF) as
po ten tial ther a pies for in flam ma tory dis eases. Un der the terms of the agree ment, Avanir was el i gi ble to
re ceive over $200 mil lion in com bined upfront and mile stone pay ments. Avanir would re ceive in creas ing
roy al ties on world wide sales of any prod uct re sult ing from the al li ance. Avanir would also re ceive re search
fund ing of up to $2.5 mil lion per year for up to four years. Both com pa nies were to con trib ute ex per tise
and in tel lec tual prop erty, and Novartis would be re spon si ble for prod uct de vel op ment ex penses. Novartis
is to as sume all con tin u ing re search and de vel op ment ac tiv i ties re lat ing to the ad vance ment to wards clin -
i cal de vel op ment of AVP 28225, the lead can di date. Avanir is to re ceive a mile stone pay ment if AVP
28225 reaches the next stage of development and is eligible to receive additional milestones through
clinical development.
BQS 481, mi totic kinesin Eg5 in hib i tor, was in pre clin i cal stud ies in 2008 for the treat ment of can cer.
Clin i cal tri als are ex pected to be gin in 2009.
LCL 161, an in hib i tor of IAP (in hib i tor of apoptosis), was in pre clin i cal stud ies in 2008 for the treat ment of
can cer. Clin i cal tri als are ex pected to begin in 2009.
BKM 120, an in hib i tor of phosphoinositide 3-kinase (PI3K), was in pre clin i cal stud ies in late 2008 for the
treat ment of can cer.
LDE 225, a SMO in hib i tor, was in pre clin i cal stud ies in 2008 for the treat ment of can cer. Clin i cal tri als are
ex pected to be gin in 2009.
Blood and Blood-Forming Organ Agents
elinogrel PRT 060128 B1C2, C1D II
ELINOGREL, an ADP re cep tor an tag o nist, for the pre ven tion and treat ment of throm bo sis in pa tients
with acute cor o nary syn drome (ACS) or un der go ing percutaneous cor o nary in ter ven tion (PCI), and for
the sec ond ary pre ven tion of myo car dial in farc tion and stroke, was in phase II de vel op ment in 2009 with
orig i na tor Portola (USA). Oral and iv for mu la tions of the agent are be ing de vel oped. Phase II tri als are on -
go ing of an iv for mu la tion in pa tients ex pe ri enc ing ST-seg ment el e va tion myo car dial in farc tion (STEMI)
in the USA and Eu rope (be gun in De cem ber 2007) and of elinogrel in com par i son with clopidogrel in the
USA in 800 pa tients un der go ing non-ur gent PCI, be gun in De cem ber 2008 and known as IN NO VATE-PCI.
Data from Portola’s phase I and phase IIa tri als have showed elinogrel to be well tol er ated and have pro -
duce pre dict able, dose-de pend ent platelet in hi bi tion. Elinogrel is also re ported to have a rapid on set of
ac tion and be re vers ible. Clin i cal tri als are planned in pa tients with acute cor o nary syn dromes (ACS) and
more broadly in patients with a prior heart attack or stroke, and those with peripheral vascular disease.
© 2009 IMS Health In cor po rated or its af fil i ates Page 86